Alzheimer's disease and immunotherapy.
Alzheimer's disease (AD) is a growing health care epidemic. It is the most common cause of dementia and its incidence is rising. Age, which influences the oxidative and inflammatory states of the brain, is the most important risk factor. Currently there is no disease modifying treatments available for this irreversible, progressive debilitating disease. Immunotherapy represents an emerging, potentially disease modifying strategy aimed at reducing the pathological lesions of AD and facilitating cognitive improvement. Many clinical trials are currently underway. This literature review highlights current knowledge regarding the physiology of aging and how it relates to the pathogenesis of AD. In addition, immunotherapy is discussed in the context of its mechanism, current studies and future goals.
Department of Medicine, Nassau University Medical Center, East Meadow, NY 11554, USA.
Jennifer
J
Madeo
Marianne
M
Frieri
Alzheimer’s disease; immunosenescence; immunotherapy; monoclonal antibodies; vaccination